FBRX
Forte Biosciences, Inc.NASDAQHealthcare$25.58+3.36%ClosedMarket Cap: $320.4M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
63.80
P/S
0.00
EV/EBITDA
-3.60
DCF Value
$0.47
FCF Yield
-15.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-98.4%
ROA
-83.8%
ROIC
-113.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | Infinity% | $-24.6M | $-24.8M | $-1.39 | — |
| FY 2025 | $0.00 | NaN% | $-70.7M | $-69.4M | $-4.71 | — |
| Q3 2025 | $0.00 | -Infinity% | $-18.4M | $-17.7M | $-0.99 | — |
| Q2 2025 | $0.00 | -Infinity% | $-11.6M | $-11.2M | $-0.96 | — |
| Q1 2025 | $0.00 | -Infinity% | $-16.1M | $-15.7M | $-1.37 | — |
| Q4 2024 | $0.00 | -Infinity% | $-7.4M | $-7.2M | $-1.12 | — |
| FY 2024 | $0.00 | -Infinity% | $-36.6M | $-35.5M | $-12.17 | — |
| Q3 2024 | $0.00 | -Infinity% | $-8.6M | $-8.4M | $-4.54 | — |
| Q2 2024 | $0.00 | -Infinity% | $-12.8M | $-12.5M | $-6.78 | — |
| Q1 2024 | $0.00 | -Infinity% | $-7.8M | $-7.4M | $-4.77 | — |
| Q4 2023 | $0.00 | -Infinity% | $-6.4M | $-5.9M | $-4.04 | — |
| FY 2023 | $0.00 | -Infinity% | $-32.5M | $-31.5M | $-24.92 | — |